Biosimilars Drug Pricing Pharmaceutical Manufacturing 
Drug Channels
JULY 23, 2024
It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. These data remain inconvenient for drug pricing flat earthers (#DPFE): When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2023.
European Pharmaceutical Review
NOVEMBER 8, 2022
In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog: Biosimilars
AUGUST 14, 2024
Gaulkin — Enacted in 2022, the Inflation Reduction Act (IRA) amended the Medicare provisions of the Social Security Act to impose several discount requirements on pharmaceutical manufacturers.
FDA Law Blog: Biosimilars
APRIL 16, 2024
Vanda Pharmaceuticals, Inc. Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drug prices increase faster than the rate of inflation must pay additional per-unit rebates to the program. Centers for Medicare and Medicaid Servs., 23-1457 (4th Cir.
FDA Law Blog: Biosimilars
OCTOBER 4, 2023
By Faraz Siddiqui — Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare Drug Price Negotiation Program. Standing The Defendants questioned, and the court reviewed, Plaintiffs’ standing.
Pharmaceutical Commerce
JUNE 13, 2025
Bill Roth Key Takeaways Price hikes, not launch prices, drove the GTN bubble. The real driver of the gross-to-net (GTN) bubble was the pharmaceutical industry's ability to raise drug prices year after year—enabled by loopholes in PBM contracts—rather than high launch prices alone.
Big Molecule Watch
MAY 15, 2025
In the past month, President Trump signed two executive orders concerning drug access and affordability, including for biologics and biosimilar drugs. 14273 (EO 273), titled Lowering Drug Prices By Once Again Putting Americans First. discounts on prices and the manufacturers that acquiesce to these price demands.
Expert insights. Personalized for you.
52 
Let's personalize your content